SOURCE: CLX Investment Company, Inc.

November 13, 2007 08:25 ET

CLX Investment Company Announces Agreement With American Health Partners, LLC for Market Readiness and Distribution Management Services

MURRIETA, CA--(Marketwire - November 13, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced a professional services agreement with American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.

The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.

AHP ( has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.

With its recent acquisition of a majority percentage of Zonda, CLX's business strategy is focused on the acquisition of innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. Zonda's medical diagnostic tests, which are based upon enzymatic detection technology, are expected to be just one area of focus for CLX, and management is seeking additional innovative products as potential acquisitions. To that end, CEO Vera Leonard has traveled to Dusseldorf, Germany to attend at MEDICA, the world's largest medical trade fair, which is being held from Nov. 14-17.

"AHP has a track record of assisting with the successful launch of new medical diagnostic testing products in the U.S. market, and we are pleased to have entered into this agreement to work with AHP on Zonda's Chlamydia product," stated Ms. Leonard. "As we review additional potential acquisition opportunities for CLX this week at MEDICA, the agreement with AHP takes on even greater significance. We expect that this relationship will be utilized for all future products that are acquired by CLX."

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About American Health Partners

American Health Partners is known for bringing medical innovations to life through a proprietary MINDMODEL™ process. The AHP market readiness and distribution management system has been utilized to introduce MedMira's Reveal™ G2 Rapid HIV-1 Antibody Test the market's fastest FDA approved HIV test and ThyroTec's ThyroTest™, the first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening device.

About CLX Investment Company

CLX Investment Company ( holds a 51% equity interest in Zonda, Inc. Information regarding Zonda can be found on its official website, CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact